Last reviewed 2026-04-23 · How we verify

Oral Glycopyrrolate Liquid

Shionogi · Phase 3 active Small molecule

Oral Glycopyrrolate Liquid is a Anticholinergic Small molecule drug developed by Shionogi. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD).

Glycopyrrolate is an anticholinergic medication that works by blocking the action of acetylcholine, a neurotransmitter that stimulates the parasympathetic nervous system, thereby reducing secretions and slowing the heart rate.

At a glance

Generic name	Oral Glycopyrrolate Liquid
Sponsor	Shionogi
Drug class	Anticholinergic
Target	Muscarinic acetylcholine receptor
Modality	Small molecule
Therapeutic area	Respiratory
Phase	Phase 3

Mechanism of action

By blocking the action of acetylcholine, glycopyrrolate reduces the amount of saliva, sweat, and mucus produced in the body. This can help to alleviate symptoms such as drooling, sweating, and respiratory secretions. Additionally, glycopyrrolate's anticholinergic effects can help to slow the heart rate and reduce the force of the heart's contractions, which can be beneficial in certain medical conditions.

Approved indications

Chronic obstructive pulmonary disease (COPD)

Common side effects

Dry mouth
Dizziness
Headache
Nausea
Vomiting
Abdominal pain
Diarrhea
Fatigue
Insomnia
Muscle weakness

Key clinical trials

Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Oral Glycopyrrolate Liquid CI brief — competitive landscape report
Oral Glycopyrrolate Liquid updates RSS · CI watch RSS
Shionogi portfolio CI

Frequently asked questions about Oral Glycopyrrolate Liquid

What is Oral Glycopyrrolate Liquid?

Oral Glycopyrrolate Liquid is a Anticholinergic drug developed by Shionogi, indicated for Chronic obstructive pulmonary disease (COPD).

How does Oral Glycopyrrolate Liquid work?

What is Oral Glycopyrrolate Liquid used for?

Oral Glycopyrrolate Liquid is indicated for Chronic obstructive pulmonary disease (COPD).

Who makes Oral Glycopyrrolate Liquid?

Oral Glycopyrrolate Liquid is developed by Shionogi (see full Shionogi pipeline at /company/shionogi).

What drug class is Oral Glycopyrrolate Liquid in?

Oral Glycopyrrolate Liquid belongs to the Anticholinergic class. See all Anticholinergic drugs at /class/anticholinergic.

What development phase is Oral Glycopyrrolate Liquid in?

Oral Glycopyrrolate Liquid is in Phase 3.

What are the side effects of Oral Glycopyrrolate Liquid?

Common side effects of Oral Glycopyrrolate Liquid include Dry mouth, Dizziness, Headache, Nausea, Vomiting, Abdominal pain.

What does Oral Glycopyrrolate Liquid target?

Oral Glycopyrrolate Liquid targets Muscarinic acetylcholine receptor and is a Anticholinergic.

Drug class: All Anticholinergic drugs
Target: All drugs targeting Muscarinic acetylcholine receptor
Manufacturer: Shionogi — full pipeline
Therapeutic area: All drugs in Respiratory
Indication: Drugs for Chronic obstructive pulmonary disease (COPD)
Compare: Oral Glycopyrrolate Liquid vs similar drugs
Pricing: Oral Glycopyrrolate Liquid cost, discount & access